DarioHealth Corp
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
DRIO$2.39+16.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENT OF CASH FLOWS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended | ||||||
| · · December 31, | ||||||
| | 2024 | 2023 | ||||
| Cash flows from operating activities: | | | | | | |
| Net loss | | $(42,747) | | $(59,427) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | | | | | ||
| Stock-based compensation | | 15,796 | | 19,701 | ||
| Depreciation and impairment | | 1,327 | | 473 | ||
| Change in operating lease right of use assets | | 907 | | 239 | ||
| Amortization of acquired intangible assets | | 6,100 | | 4,512 | ||
| Decrease in trade receivables, net | | 1,680 | | 3,261 | ||
| Increase in other accounts receivable, prepaid expense and long-term assets | | (80) | | (426) | ||
| Decrease in inventories | | 308 | | 2,894 | ||
| Decrease in trade payables | | (496) | | (1,191) | ||
| Decrease in other accounts payable and accrued expenses | | (3,483) | | (256) | ||
| Decrease in deferred revenues | | (156) | | (323) | ||
| Change in operating lease liabilities | | (1,150) | | (124) | ||
| Change in fair value of warrant liability | | (16,504) | | (670) | ||
| Non-Cash financial expenses | | 516 | | 1,198 | ||
| Other | | (580) | | (240) | ||
| | | | | | | |
| Net cash used in operating activities | | (38,562) | | (30,379) | ||
| | | | | | | |
| Cash flows from investing activities: | | | ||||
| Purchase of property and equipment | | (138) | | (584) | ||
| Purchase of short-term investments | | | — | | | (4,996) |
| Proceeds from redemption of short-term investments | | | — | | | 5,033 |
| Payments for business acquisitions, net of cash acquired | | | (8,796) | | | — |
| | | | | | | |
| Net cash used in investing activities | | (8,934) | | (547) | ||
| | | | | | | |
| Cash flows from financing activities: | | | | | ||
| Proceeds from issuance of common stock, net of issuance costs | | | — | | | 1,614 |
| Proceeds from issuance of preferred stock, net of issuance costs | | 38,531 | | 14,868 | ||
| Proceeds from borrowings on credit agreement | | | — | | | 29,604 |
| Repayment of long-term loan | | | — | | | (27,833) |
| | | | | | | |
| Net cash provided by financing activities | | 38,531 | | 18,253 | ||
| | | | | | | |
| Decrease in cash, cash equivalents and restricted cash and cash equivalents | | (8,965) | | (12,673) | ||
| Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents | | | (68) | | | — |
| Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | | 36,797 | | 49,470 | ||
| Cash, cash equivalents and restricted cash and cash equivalents at end of period | | $27,764 | | $36,797 | ||
| Supplemental disclosure of cash flow information: | | | | |||
| Cash paid during the period for interest on long-term loan | | $3,927 | | $4,031 | ||
| Non-cash activities: | | | | |||
| Right-of-use assets obtained in exchange for lease liabilities | | $428 | | $136 | ||
| Exercise of pre-funded warrant to common stock upon acquisition | | $2,225 | | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.